Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Immunotherapy Shows Activity Among Patients With Gynecologic Clear Cell Carcinoma

Don Dizon, MD

 

Don Dizon, MD, Lifespan Cancer Institute, Providence, Rhode Island, shares insights from the phase 2 BrUOG 354 trial evaluating nivolumab with or without ipilimumab among patients with ovarian and extra-renal clear cell carcinomas.

According to Dr Dizon and coauthors, nivolumab plus ipilimumab “warrant further evaluation against standard treatment for people with ovarian [clear cell carcinoma], given the historically chemotherapy-resistant nature of the disease.


Source:

Dizon D, Mathews CA, MacLaughlan David S, et al. Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract #LBA5500

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement